ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases

Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held multiple senior R&D leadership roles in the pharmaceutical industry and will continue to be minority shareholders. The company has been advised by Bruce Leuchter from... Source: RealWire

from healthcare-mental health feed from realwire http://bit.ly/2F6MVB2